Fairmount Funds Management LLC (Kiselak Tomas, Harwin Peter Evan) sold (to issuer) 443,187 shares of APGE (indirect holdings)
Fairmount Funds Management LLC sold (to issuer) 443,187 indirectly-held shares of Apogee Therapeutics, Inc. (APGE) across 3 trades on 2026-09-03. Filed jointly with Fairmount Healthcare Fund II L.P. (Director), Kiselak Tomas (Director) and Harwin Peter Evan (Director).
How this was made
The 30-second read
Why it matters
The complete divestiture by a director may signal reduced insider confidence, potentially influencing investor perception.
Market read
Primary insider sale; modest trading relevance for APGE.
What to watch
No disclosed price; the sale may have been part of a pre-arranged plan or tax strategy.
Background
Form 4 filings disclose insider transactions; directors must report sales promptly.
Ticker impact
Director and related parties sold their entire indirect holdings of 443,187 shares on 2026-09-03 via a Form 4 filing.
Potential short-term downward pressure on APGE as the market digests the insider exit.
Large insider sell of a director's full position is a material signal, but no price disclosed and no broader context.
Market effects
Minimal; biotech sector may see slight sentiment drag from insider sell.
U.S. biotech investors may note the sale, but no broader regional effect.
Low; isolated to APGE.
Counterpoint
The sale could be unrelated to confidence and driven by personal liquidity needs.
Key entities
- CompanyApogee Therapeutics, Inc.
Biotech firm listed on NASDAQ under APGE.
- InvestorFairmount Funds Management LLC
Reporting entity and director of APGE.
